Navigation Links
Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Date:10/8/2008

PT. RICHMOND, Calif., Oct. 8 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Thomas P. Soloway, Senior Vice President and Chief Financial Officer, is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City on Monday, October 13, 2008 at 9:30 AM Eastern Time.

An audio webcast of the presentation will be available at http://www.wsw.com/webcast/nblr2/transcept/ and on the Transcept website at http://www.transcept.com. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration. For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals Appoints Key Senior Executives
2. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
3. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
8. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
9. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
10. Alseres Pharmaceuticals, Inc. Raises $5 Million
11. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring ... kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):